June 2018: Awarded second SBIR grant; now supported by National Science Foundation
ARTICULATE BIOSCIENCES IS DEVELOPING
ABX VISCOELASTICS:
Injectable gels for treating arthritis and other soft tissue diseases
ABX TECHNOLOGY:
Biocompatible, cushioning, & lubricating
Tissue-protecting and function-restoring biomedical polymers
Our first product candidate will relieve pain and restore mobility to sufferers of osteoarthritis.
OUR TEAM
OUR PARTNERS
ABOUT
Spun out of Boston University in 2016, Articulate Biosciences is a preclinical stage medical device company. We are seeking rapid growth to expand our team and develop a portfolio of products for several key indications in orthopedics and soft tissue repair.
Using our patented ABX platform technology, our mission is to deliver long-lasting pain relief and restoration of mobility to sufferers of osteoarthritis. Through deep understanding of patient and clinician needs, combined with innovative breakthroughs in medical device technology, Articulate Biosciences strives to bring back quality of life by eliminating chronic joint pain
NEWS
June 2018
AWARDED $225,000 PHASE I SBIR GRANT (NSF)
March 2018
ARTICULATE SELECTED AS AUDIENCE FAVORITE, MASS INNOVATION NIGHT
January 2018
ARTICULATE SELECTED AS A JLABS COMPANY
January 2018
UNITED STATES PATENT COVERING ABX TECHNOLOGY IS ISSUED
September 2017
AWARDED $200,000 PHASE I SBIR GRANT (NIH)
July 2017
PARTICIPANT IN THE NSF I-CORPS PROGRAM
April 2017
WINNER IN THE MA MEDICAL DEVICE DEVELOPMENT CENTER (M2D2) $100K CHALLENGE
July 2016
PARTICIPANT IN THE BOSTON UNIVERSITY QUESTROM SCHOOL OF BUSINESS SUMMER ACCELERATOR
January 2016
ARTICULATE BIOSCIENCES IS FOUNDED
July 2015
PROF. MARK GRINSTAFF AWARDED $225,000 BOSTON UNIVERSITY & COULTER FOUNDATION GRANT
CONTACT
Articulate Biosciences
JLABS @ Massachusetts Medical Device Development Center (M2D2) Incubator
110 Canal Street, 4th floor
Lowell, MA 01852